Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21619469 | 0.89 | CYP2D6 (0.30) | CYP2D6KCNH2HRH3 | |
| SCHEMBL24952558 | 0.85 | CCR2 (0.33) | CCR2CYP2D6KCNH2HRH3 | |
| SCHEMBL2737209 | 0.85 | CCR2 (0.33) | CCR2 | |
| SCHEMBL15503189 | 0.82 | CCR2 (0.31) | CCR2 | |
| SCHEMBL24411699 | 0.79 | CYP2D6 (0.33) | CYP2D6KCNH2HRH3 | |
| SCHEMBL23109381 | 0.75 | CCR2 (0.31) | CCR2KCNH2 | |
| SCHEMBL3099099 | 0.74 | BIRC2 (0.34) | CCR2KCNH2HRH3 | |
| SCHEMBL12339303 | 0.74 | BIRC2 (0.34) | CCR2KCNH2HRH3 | |
| SCHEMBL2760223 | 0.74 | BIRC2 (0.34) | CCR2KCNH2HRH3 | |
| SCHEMBL19223437 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | CCR2 1750/4885CYP2D6 3665/4885KCNH2 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.